BioForce Nanosciences Holdings, Inc. announces Mr. Merle Ferguson as its new CEO

Mr. Ferguson brings to BioForce Nanosciences Holdings business acumen from both the public and private business arenas.

Further, BioForce Nanosciences Holdings, Inc.'s business focuses on the acquisition of services, productions, and agricultural facilities within the food services sector.

You may also like

Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Manufacturing

Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger

Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Subscribe now